Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site

Conclusions Pazopanib exhibits extensive binding to plasma proteins in human plasma. Variable albumin concentrations, frequently observed in cancer patients, may affect pazopanib unbound fraction with implications for inter-patient variability in drug efficacy and toxicity.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research